Inventor · disambiguated record
Ronald A. Depinho
Also filed as: DEPINHO RONALD · DEPINHO RONALD A
24 granted patents·25 pending applications·194 citations·filing 1996–2021
95Inventor score
Top patents by PatentIndex Score
49 records- 0193US8211634B2Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancerDEPINHO RONALD A·Filed 2007·Granted Jul 3, 2012·37 cites·16 claims
- 0291US6639121B1Inducible cancer model to study the molecular basis of host tumor cell interactions in vivoDANA FARBER CANCER INST INC·Filed 2000·Granted Oct 28, 2003·27 cites·47 claims
- 0390US8168602B2Compositions, kits and methods for identification, assessment, prevention and therapy of cancerDEPINHO RONALD A·Filed 2006·Granted May 1, 2012·15 cites·7 claims
- 0486US9309564B2Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancerDEPINHO RONALD A·Filed 2012·Granted Apr 12, 2016·5 cites·10 claims
- 0582US9745631B2Methods for diagnosing and treating oncogenic kras-associated cancerDANA FARBER CANCER INST INC·Filed 2012·Granted Aug 29, 2017·4 cites·12 claims
- 0680US6767719B1Mouse telomerase reverse transcriptaseGERON CORP·Filed 1998·Granted Jul 27, 2004·43 cites·21 claims
- 0779US6897197B2Method of inhibiting cell proliferation using an anti-oncogene proteinEINSTEIN COLL MED·Filed 2003·Granted May 24, 2005·4 cites·2 claims
- 0878US9632090B2Compositions and methods for the identification, assessment, prevention and therapy of thymic lymphoma or hamartomatous tumoursDEPINHO RONALD A·Filed 2010·Granted Apr 25, 2017·6 cites·10 claims
- 0974US10363261B2Enolase inhibitors and methods of treatment therewithUNIV TEXAS·Filed 2016·Granted Jul 30, 2019·2 cites·19 claims
- 1073US8999633B2Compositions, kits, and methods for identification, assessment, prevention and treatment of pancreatic adenocarcinoma in humansCHIN LYNDA·Filed 2005·Granted Apr 7, 2015·3 cites·3 claims
- 1172US6680371B2Myc homology region II-associated protein and uses thereofEINSTEIN COLL MED·Filed 2001·Granted Jan 20, 2004·1 cites·3 claims
- 1270US9458510B2Signatures and determinants associated with prostate cancer progression and methods of use thereofDEPINHO RONALD A·Filed 2012·Granted Oct 4, 2016·2 cites·12 claims
- 1364US5919997ATransgenic mice having modified cell-cycle regulationCOLD SPRING HARBOR LAB·Filed 1996·Granted Jul 6, 1999·26 cites·11 claims
- 1462US9687548B2Photoactivatable caged tamoxifen and tamoxifen derivative molecules and methods of use thereofDANA FARBER CANCER INST INC·Filed 2013·Granted Jun 27, 2017·0 cites·17 claims
- 1562US9452182B2Collateral gene inactivation biomarkers and targets for cancer therapyUNIV TEXAS·Filed 2012·Granted Sep 27, 2016·2 cites·20 claims
- 1661US2020232988A1Signatures and determinants associated with prostate cancer progression and methods of use thereofDANA FARBER CANCER INST INC·Filed 2019·Application pending·0 cites
- 1760US2010255004A1Receptor tyrosine kinase profilingDANA FARBER CANCER INST INC·Filed 2008·Application pending·0 cites
- 1859US10378060B2ZNF365/ZFP365 biomarker predictive of anti-cancer responseDANA FARBER CANCER INST INC·Filed 2012·Granted Aug 13, 2019·1 cites·9 claims
- 1959US2004043437A1Inducible cancer model to study the molecular basis of host tumor cell interactions in vivoFiled 2003·Application pending·0 cites
- 2058US2011265197A1Signatures and PCDeterminants Associated with Prostate Cancer and Methods of Use ThereofDANA FARBER CANCER INST INC·Filed 2009·Application pending·0 cites
- 2158US2007107076A1Inducible cancer model to study the molecular basis of host tumor cell interactions in vivoDEPINHO RONALD A·Filed 2006·Application pending·0 cites
- 2258US2023406949A1Combinatorial immunotherapeutic methods and compositions for pancreatic ductal adenocarcinoma treatmentUNIV TEXAS·Filed 2021·Application pending·0 cites
- 2356US2009111157A1Protein and peptide fragments from mouse telomerase reverse transcriptaseGERON CORP·Filed 2007·Application pending·0 cites
- 2456US2017340736A1Photoactivatable caged tamoxifen and tamoxifen derivative molecules and methods of use thereofDANA FARBER CANCER INST INC·Filed 2017·Application pending·0 cites
- 2555US7371515B2Identifying and characterizing genesDANA FARBER CANCER INST INC·Filed 2002·Granted May 13, 2008·1 cites·7 claims
- 2655US2022235348A1Crispr methods for treating cancersUNIV TEXAS·Filed 2020·Application pending·0 cites
- 2755US2023250433A1Methods and compositions for treatment of apc-deficient cancerUNIV TEXAS·Filed 2021·Application pending·0 cites
- 2853US2018074062A1Compositions and methods for the identification, assessment, prevention and therapy of cancerDANA FARBER CANCER INST INC·Filed 2017·Application pending·0 cites
- 2951US7622630B2Chimeric cancer modelsAVEO PHARMACEUTICALS INC·Filed 2004·Granted Nov 24, 2009·1 cites·6 claims
- 3051US2016363596A1Signatures and determinants associated with prostate cancer progression and methods of use thereofDEPINHO RONALD A·Filed 2016·Application pending·0 cites
- 3151US2010298158A1Compositions, Kits, and Methods for Identification, Assessment, Prevention, and Therapy of CancerDANA FARBER CANCER INST INC·Filed 2008·Application pending·0 cites
- 3251US2022313782A1Methods and compositions involving tert activating therapiesUNIV TEXAS·Filed 2020·Application pending·0 cites
- 3351US2003226159A1Cancer modelsFiled 2003·Application pending·0 cites
- 3450US2014235479A1Signatures and pcdeterminants associated with prostate cancer and methods of use thereofDEPINHO RONALD A·Filed 2014·Application pending·0 cites
- 3550US2014011748A1Methods Of Predicting Response To JNK Inhibitor TherapyCHIN LYNDA·Filed 2012·Application pending·0 cites
- 3649US6040425AMyc homology region II--associated proteinEINSTEIN COLL MED·Filed 1997·Granted Mar 21, 2000·5 cites·1 claims
- 3749US2008194019A1Tumor Suppressor Lkb1 Kinase Directly Activates Amp-Activated KinaseBETH ISRAEL HOSPITAL·Filed 2004·Application pending·0 cites
- 3845US2011030074A1Compositions and methods for cancer gene discoveryDANA FARBER CANCER INST INC·Filed 2008·Application pending·0 cites
- 3945US2017299594A1Signatures and pcdeterminants associated with prostate cancer and methods of use thereofDEPINHO RONALD A·Filed 2016·Application pending·0 cites
- 4043US7595158B2Bcl2L12 polypeptide activators and inhibitorsDANA FARBER CANCER INST INC·Filed 2005·Granted Sep 29, 2009·0 cites·20 claims
- 4143US2012122991A1Method for treating cancer by increasing amp-activated kinase activityCANTLEY LEWIS C·Filed 2012·Application pending·0 cites
- 4240US5811298ARep-max protein having anti-oncogenic activity and uses thereofEINSTEIN COLL MED·Filed 1996·Granted Sep 22, 1998·3 cites·9 claims
- 4339US2010297072A1Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer TherapyDEPINHO RONALD A·Filed 2010·Application pending·0 cites
- 4439US2010092476A1Pancreatic cancer biomarkersHANASH SAMIR M·Filed 2007·Application pending·0 cites
- 4538US6613750B2Method of inhibiting cell proliferation using an anti-oncogene proteinEINSTEIN COLL MED·Filed 1998·Granted Sep 2, 2003·3 cites·2 claims
- 4638US2008242742A1Animal models of pancreatic adenocarcinoma and uses thereforDANA FARBER CANCER INST INC·Filed 2006·Application pending·0 cites
- 4737US6140476ARep-max protein having anti-oncogenic activity and uses thereofEINSTEIN COLL MED·Filed 1998·Granted Oct 31, 2000·2 cites·2 claims
- 4837US2013040853A1Context Specific Genetic Screen Platform to Aid in Gene Discovery and Target ValidationDANA FARBER CANCER INST INC·Filed 2011·Application pending·0 cites
- 4935US6297368B1Myc homology region II—associated protein and uses thereofEINSTEIN COLL MED·Filed 2000·Granted Oct 2, 2001·1 cites·2 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →